HUE035699T2 - Preparation containing amino acids for use in the treatment of systemic inflammatory conditions in stroke patients suffering from swallowing difficulties - Google Patents
Preparation containing amino acids for use in the treatment of systemic inflammatory conditions in stroke patients suffering from swallowing difficulties Download PDFInfo
- Publication number
- HUE035699T2 HUE035699T2 HUE15187946A HUE15187946A HUE035699T2 HU E035699 T2 HUE035699 T2 HU E035699T2 HU E15187946 A HUE15187946 A HU E15187946A HU E15187946 A HUE15187946 A HU E15187946A HU E035699 T2 HUE035699 T2 HU E035699T2
- Authority
- HU
- Hungary
- Prior art keywords
- patients
- composition
- stroke
- amino acids
- dysphagia
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 107
- 208000006011 Stroke Diseases 0.000 title claims description 77
- 150000001413 amino acids Chemical class 0.000 title claims description 63
- 230000009885 systemic effect Effects 0.000 title claims description 20
- 208000019505 Deglutition disease Diseases 0.000 title description 70
- 230000004054 inflammatory process Effects 0.000 title description 26
- 206010061218 Inflammation Diseases 0.000 title description 25
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 37
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 37
- 239000013543 active substance Substances 0.000 claims description 25
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 24
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 21
- 239000004474 valine Substances 0.000 claims description 21
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 19
- 229930182817 methionine Natural products 0.000 claims description 18
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 18
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 16
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 16
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 14
- 239000002562 thickening agent Substances 0.000 claims description 10
- 235000014633 carbohydrates Nutrition 0.000 claims description 8
- 230000009747 swallowing Effects 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000019156 vitamin B Nutrition 0.000 claims description 5
- 239000011720 vitamin B Substances 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 241001388119 Anisotremus surinamensis Species 0.000 claims 1
- 235000013162 Cocos nucifera Nutrition 0.000 claims 1
- 244000060011 Cocos nucifera Species 0.000 claims 1
- 108010044467 Isoenzymes Proteins 0.000 claims 1
- 229930003270 Vitamin B Natural products 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 235000020776 essential amino acid Nutrition 0.000 description 77
- 239000003797 essential amino acid Substances 0.000 description 77
- 229940024606 amino acid Drugs 0.000 description 60
- 235000001014 amino acid Nutrition 0.000 description 60
- 210000003205 muscle Anatomy 0.000 description 46
- 210000002751 lymph Anatomy 0.000 description 44
- 229960003136 leucine Drugs 0.000 description 33
- 235000005772 leucine Nutrition 0.000 description 33
- 230000014616 translation Effects 0.000 description 27
- 238000001243 protein synthesis Methods 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 23
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 21
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 21
- 230000037396 body weight Effects 0.000 description 20
- 229960000310 isoleucine Drugs 0.000 description 20
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 229960004295 valine Drugs 0.000 description 19
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 18
- 239000004472 Lysine Substances 0.000 description 18
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 18
- 235000018977 lysine Nutrition 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 239000000902 placebo Substances 0.000 description 18
- 229940068196 placebo Drugs 0.000 description 18
- 229960004799 tryptophan Drugs 0.000 description 18
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 17
- 102000008934 Muscle Proteins Human genes 0.000 description 17
- 108010074084 Muscle Proteins Proteins 0.000 description 17
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 17
- 230000017854 proteolysis Effects 0.000 description 17
- 229960002898 threonine Drugs 0.000 description 17
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 16
- 239000004473 Threonine Substances 0.000 description 14
- 230000001154 acute effect Effects 0.000 description 14
- 229960002885 histidine Drugs 0.000 description 14
- 235000014304 histidine Nutrition 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 235000008521 threonine Nutrition 0.000 description 14
- 229960004441 tyrosine Drugs 0.000 description 14
- 230000009748 deglutition Effects 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 12
- 230000002757 inflammatory effect Effects 0.000 description 12
- 229960005190 phenylalanine Drugs 0.000 description 12
- 230000001976 improved effect Effects 0.000 description 11
- 230000022558 protein metabolic process Effects 0.000 description 11
- 230000001195 anabolic effect Effects 0.000 description 10
- 229960003067 cystine Drugs 0.000 description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 10
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 9
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 9
- 206010049645 Hypercatabolism Diseases 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 229960003646 lysine Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- -1 phenyl- Chemical group 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010048998 Acute phase reaction Diseases 0.000 description 7
- 229920000084 Gum arabic Polymers 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 7
- 230000004658 acute-phase response Effects 0.000 description 7
- 235000004279 alanine Nutrition 0.000 description 7
- 229960003767 alanine Drugs 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000007574 infarction Effects 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 229960004452 methionine Drugs 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- 229920002752 Konjac Polymers 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- 239000000205 acacia gum Substances 0.000 description 6
- 235000010489 acacia gum Nutrition 0.000 description 6
- 229960001230 asparagine Drugs 0.000 description 6
- 235000009582 asparagine Nutrition 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000010485 konjac Nutrition 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 229920002774 Maltodextrin Polymers 0.000 description 5
- 108010071690 Prealbumin Proteins 0.000 description 5
- 102000007584 Prealbumin Human genes 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 102000004338 Transferrin Human genes 0.000 description 5
- 108090000901 Transferrin Proteins 0.000 description 5
- 229930003451 Vitamin B1 Natural products 0.000 description 5
- 210000005006 adaptive immune system Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 235000018823 dietary intake Nutrition 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 235000004554 glutamine Nutrition 0.000 description 5
- 230000002650 habitual effect Effects 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960003080 taurine Drugs 0.000 description 5
- 229960003495 thiamine Drugs 0.000 description 5
- 239000012581 transferrin Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 235000010374 vitamin B1 Nutrition 0.000 description 5
- 239000011691 vitamin B1 Substances 0.000 description 5
- 235000019158 vitamin B6 Nutrition 0.000 description 5
- 239000011726 vitamin B6 Substances 0.000 description 5
- 229940011671 vitamin b6 Drugs 0.000 description 5
- 229920002581 Glucomannan Polymers 0.000 description 4
- 102000014702 Haptoglobin Human genes 0.000 description 4
- 108050005077 Haptoglobin Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 208000002720 Malnutrition Diseases 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 229940046240 glucomannan Drugs 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 235000021075 protein intake Nutrition 0.000 description 4
- 230000004844 protein turnover Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 3
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 229960002743 glutamine Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 201000000585 muscular atrophy Diseases 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- JWJCTZKFYGDABJ-UHFFFAOYSA-N Metanephrine Chemical compound CNCC(O)C1=CC=C(O)C(OC)=C1 JWJCTZKFYGDABJ-UHFFFAOYSA-N 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000006035 Tryptophane Substances 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000002157 hypercatabolic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000252 konjac Substances 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000035771 neuroregeneration Effects 0.000 description 2
- 238000001584 occupational therapy Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002630 speech therapy Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 235000000112 undernutrition Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 241001080024 Telles Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 208000012764 acute weight loss Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000002975 glyconeogenic effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 208000037907 haemorrhagic injury Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003166 hypermetabolic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003585 interneuronal effect Effects 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000018731 motor weakness Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITTO20140806 | 2014-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE035699T2 true HUE035699T2 (en) | 2018-05-28 |
Family
ID=52101507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15187946A HUE035699T2 (en) | 2014-10-08 | 2015-10-01 | Preparation containing amino acids for use in the treatment of systemic inflammatory conditions in stroke patients suffering from swallowing difficulties |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9707198B2 (enExample) |
| EP (1) | EP3006027B1 (enExample) |
| JP (1) | JP6447716B2 (enExample) |
| KR (1) | KR102077374B1 (enExample) |
| AU (1) | AU2015329581B2 (enExample) |
| CA (1) | CA2958033C (enExample) |
| DK (1) | DK3006027T3 (enExample) |
| ES (1) | ES2651903T3 (enExample) |
| HU (1) | HUE035699T2 (enExample) |
| NO (1) | NO3006027T3 (enExample) |
| NZ (1) | NZ728962A (enExample) |
| PL (1) | PL3006027T3 (enExample) |
| RU (1) | RU2668373C1 (enExample) |
| WO (1) | WO2016055948A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3294279T3 (pl) * | 2015-05-14 | 2020-06-29 | Professional Dietetics International S.R.L. | Kompozycje zawierające aminokwasy do zastosowania w leczeniu zapalenia błony śluzowej u pacjentów cierpiących na neoplazję poddawanych radioterapii i/lub chemioterapii |
| IT201700087376A1 (it) * | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4780475A (en) * | 1986-02-03 | 1988-10-25 | Cerra Frank B | Preparation for the prevention of catabolism |
| US5276018A (en) * | 1992-07-17 | 1994-01-04 | Brigham And Women's Hospital | Composition comprising amino acids and methods for decreasing muscle breakdown |
| IT1320783B1 (it) * | 2000-07-04 | 2003-12-10 | Professional Dietetics Srl | Composizioni a base di aminoacidi, atte al miglioramento delleprestazioni muscolari. |
| US20030060421A1 (en) * | 2001-07-19 | 2003-03-27 | Neuron Therapeutics, Inc. | Kits and compositions supporting intracranial perfusions |
| EP2275084A1 (en) * | 2009-07-15 | 2011-01-19 | Unilever PLC | Oral care composition |
| RU2012105901A (ru) * | 2009-07-20 | 2013-08-27 | Нестек С.А. | Способы снижения потери функционального состояния |
| PH12013501571A1 (en) * | 2011-03-01 | 2013-09-30 | Nestec Sa | Extensional viscosity to promote safe swallowing of food boluses |
| WO2012133198A1 (ja) * | 2011-03-25 | 2012-10-04 | イーエヌ大塚製薬株式会社 | 炎症性疾患用栄養組成物 |
| JP2012214451A (ja) * | 2011-03-25 | 2012-11-08 | En Otsuka Pharmaceutical Co Ltd | 炎症性疾患用アミノ酸組成物 |
| JP5837315B2 (ja) * | 2011-03-25 | 2015-12-24 | イーエヌ大塚製薬株式会社 | 炎症性疾患用栄養組成物 |
| WO2012142678A1 (en) * | 2011-04-21 | 2012-10-26 | Fit-Bioceuticals Limited | Weight loss composition |
| RU2526826C2 (ru) * | 2012-10-24 | 2014-08-27 | Николай Владимирович Соловьёв | Композиция для парентерального введения, способ получения и применение композиции |
-
2015
- 2015-10-01 NO NO15187946A patent/NO3006027T3/no unknown
- 2015-10-01 ES ES15187946.7T patent/ES2651903T3/es active Active
- 2015-10-01 HU HUE15187946A patent/HUE035699T2/en unknown
- 2015-10-01 DK DK15187946.7T patent/DK3006027T3/en active
- 2015-10-01 EP EP15187946.7A patent/EP3006027B1/en active Active
- 2015-10-01 PL PL15187946T patent/PL3006027T3/pl unknown
- 2015-10-07 JP JP2017511782A patent/JP6447716B2/ja not_active Expired - Fee Related
- 2015-10-07 KR KR1020177009224A patent/KR102077374B1/ko not_active Expired - Fee Related
- 2015-10-07 WO PCT/IB2015/057662 patent/WO2016055948A1/en not_active Ceased
- 2015-10-07 NZ NZ728962A patent/NZ728962A/en not_active IP Right Cessation
- 2015-10-07 AU AU2015329581A patent/AU2015329581B2/en not_active Ceased
- 2015-10-07 RU RU2017112492A patent/RU2668373C1/ru active
- 2015-10-07 CA CA2958033A patent/CA2958033C/en active Active
- 2015-10-08 US US14/878,100 patent/US9707198B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016055948A1 (en) | 2016-04-14 |
| AU2015329581B2 (en) | 2019-02-07 |
| AU2015329581A1 (en) | 2017-03-02 |
| RU2668373C1 (ru) | 2018-09-28 |
| ES2651903T3 (es) | 2018-01-30 |
| KR102077374B1 (ko) | 2020-02-13 |
| CA2958033A1 (en) | 2016-04-14 |
| KR20170057308A (ko) | 2017-05-24 |
| NO3006027T3 (enExample) | 2018-04-14 |
| JP2017530103A (ja) | 2017-10-12 |
| JP6447716B2 (ja) | 2019-01-09 |
| NZ728962A (en) | 2019-05-31 |
| CA2958033C (en) | 2019-07-16 |
| EP3006027A1 (en) | 2016-04-13 |
| US9707198B2 (en) | 2017-07-18 |
| US20160101078A1 (en) | 2016-04-14 |
| EP3006027B1 (en) | 2017-11-15 |
| DK3006027T3 (en) | 2017-12-18 |
| PL3006027T3 (pl) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bo et al. | A high whey protein, vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults: A double-blind randomized controlled trial | |
| Børsheim et al. | Effect of amino acid supplementation on muscle mass, strength and physical function in elderly | |
| Storms et al. | Effects of gluten on schizophrenics | |
| JP6138048B2 (ja) | システインペプチド含有健康飲料 | |
| JP2008534599A (ja) | 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物 | |
| JPWO2009057775A1 (ja) | アミノ酸組成物を含有する疲労防止剤 | |
| Aquilani et al. | Unaffected arm muscle hypercatabolism in dysphagic subacute stroke patients: the effects of essential amino acid supplementation | |
| Fouque | Nutritional requirements in maintenance hemodialysis | |
| WO2018097734A1 (en) | Prevention and/or treatment of hyperlactataemia | |
| DK3006027T3 (en) | Compositions comprising amino acids for use in the treatment of systemic inflammation associated with stroke in dysphagia patients | |
| CA2985564C (en) | Compositions comprising cinnamaldehyde and zinc and methods of using such compositions | |
| KR20160025808A (ko) | 데커신 및/또는 데커시놀 안젤레이트 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물, 쌀눈 추출물, 무말랭이 추출물을 유효성분으로 포함하는 피로 또는 스트레스의 예방 또는 회복용 조성물 | |
| CN108371326B (zh) | 一种降血糖的功能性组合物 | |
| US12576068B2 (en) | Compositions containing amino acids and methods of using such compositions for treating sarcopenia | |
| Fraser et al. | Nutrition issues following spinal cord injury | |
| CN103298478A (zh) | 血中gip浓度上升抑制剂、血中胰岛素浓度上升抑制剂、餐后血中甘油三酯浓度降低剂和血糖浓度上升抑制剂 | |
| JP2023530485A (ja) | 運動なしで、筋量、筋力および筋機能を改善するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用法 | |
| HK40082928A (en) | Compositions containing amino acids and methods of using such compositions for treating sarcopenia | |
| WEIGHT-LOSS | TRACK 5a: MANAGEMENT-OBESITY MANAGEMENT T5: P5a-002 |